Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00273390
Status:
COMPLETED
Last Update Posted:
2011-07-04
First Post:
2006-01-05
Brief Title:
A Clinical Trial of Infliximab for Uveitis
Sponsor:
Oregon Health and Science University
Organization:
Oregon Health and Science University
Study Overview
Official Title:
The Use of Remicade Infliximab in the Management of Vision-threatening Uveitis That is Refractory to Other Modes of Systemic Immunosuppression
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This project is designed to test the hypothesis that inhibition of binding between tumor necrosis factor alpha TNF-alpha and its receptors using Remicade infliximab chimeric mousehuman IgG1K monoclonal antibody directed against human TNF-alpha Centocor MalvernPA is clinically useful for patients with uveitis that is refractory to other forms of systemic immunosuppressive therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None